Emerging platforms, clinical progress and key translational points for in vivo CAR-T therapy. (IMAGE)

Science China Press

Emerging platforms, clinical progress and key translational points for in vivo CAR-T therapy.

Caption

(a) Schematic of the in vivo CAR-T cell therapy process; (b) Clinically validated delivery platforms including LNP-based systems and viral vectors; (c) Emerging future directions for durable and low-immunogenic CAR expression; (d) Landscape of ongoing and completed clinical trials; (e) Key translational considerations and challenges.LNP: Lipid Nanoparticle; AAV: Adeno-Associated Virus; CAR: Chimeric Antigen Receptor; SLE: Systemic Lupus Erythematosus; MS: Multiple Sclerosis.

Credit

©Science China Press

Usage Restrictions

Use with credit.

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.